GreenLight Biosciences

GreenLight Biosciences

An industrial biotechnology company using a bioprocessing platform to produce chemical products.

GreenLight Biosciences is a privately held biotechnology company based in Medford, Massachusetts that was founded in 2009 by Andrey J. Zarur and Marta Ortega-Valle. The company focuses on sustainable production of chemicals and fuels using its patented cell-free bioprocessing technology platform. It develops RNA products for plant and life science applications, and collaborates with companies from various industries for vaccine development, pandemic preparation, crop management, and plant protection.

Partnerships
AgroSpheres

In October 2018, GreenLight entered into a research collaboration with AgroSpheres to study the delivery of GreenLight's double stranded RNA (dsRNA) using AgroSphere's proprietary bioparticle platform.

Funding
Series A

On July 10, 2009 Greenlight Biosciences completed their series A funding round with $4.29 million in funding from undisclosed investors.

Series B

On December 20, 2013 Greenlight Biosciences completed their series B funding round with $10.5 million in funding from undisclosed investors.

Series C

On June 15, 2015 Greenlight Biosciences completed their series C funding round with $20 million in funding from undisclosed investors.

Series D

On September 13, 2017 Greenlight Biosciences completed their series D funding round with $18 million in funding from Fall Line Capital (lead investor), S2G Ventures, Lewis and Clark Ventures, Macro Capital Investments, Kodiak Venture Partners, MLSCF, Syngenta Ventures, and other previous investors. The company is planning on using their series D funding to speed up the development of field testing several of the companies dsRNA molecules for targeting insects and viral pests in high-value crop products.

Venture

On January 8, 2019 Greenlight Biosciences completed a venture capital funding round with $50 million in funding from S2G Ventures (lead investor), Baird Capital (lead investor), Blue I/O (lead investor), Continental Grain Company, Tao Capital Partners, Alexandria Venture Investments, and several previous investors. The company plans on using the funding to expand their research and development platform for bio-control products, human and animal vaccines, and therapeutics.

Timeline

June 16, 2020
GreenLight Biosciences raises a $102,000,000 series D round from Baird Capital, Continental Grain Company, Cormorant Asset Management, Fall Line Capital, Lewis & Clark Ventures, Lupa Systems, Morningside Venture Partners, S2G Ventures and Tao Capital Partners.
May 12, 2020
GreenLight Biosciences raises a $17,000,000 venture round from Baird Capital and Xeraya Capital.
September 13, 2017
GreenLight Biosciences raises a $18,000,000 series D round from Fall Line Capital, Lewis & Clark Ventures, Macro Capital Investments and S2G Ventures.
June 17, 2015
GreenLight Biosciences raises a $20,000,000 series B round.
December 20, 2013
GreenLight Biosciences raises a $1,000,000 series A round.
August 12, 2013
GreenLight Biosciences raises a $7,000,000 series A round from Khosla Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
GreenLight Biosciences Series D round, June 16, 2020
102,000,000
June 16, 2020
7 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Andrey J. Zarur

Co-Founder, President, & CEO

Carole Cobb

COO

Drew Cunningham

Director of Platform R&D

Eric O'Brien

Investor

Marta Ortega-Valle

Co-Founder, Senior VP, Corporate Development

Nicholas Skizim

Manager of Analytical Chemistry

Sandrine Boissel

Employee

Further reading

Title
Author
Link
Type
Date

AgroSpheres enters research collaboration with GreenLight Biosciences - Virginia Bio

Web

GreenLight Biosciences aims at a revolution in the chemical industry

Don Seiffert

Web

GreenLight Biosciences Announces $50 Million Funding Round

GreenLight Biosciences, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
GreenLight Biosciences, Inc.
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health,...
Patricia Kelly Yeo
February 4, 2021
Business Insider
Insider compiled the top biotech startups tackling the world's major pathogens and preparing us for the next pandemic.
GreenLight Biosciences, Inc.
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design and manufacturing for human, animal and plant health,...
State House News Service
May 13, 2020
Boston Herald
A Medford biotech company that specializes in RNA-based products for the agriculture and pharmaceutical industries is shifting its focus toward the effort to develop and manufacture an effective vaccine for COVID-19.
Mark Terry
May 13, 2020
BioSpace
GreenLight Biosciences closed an oversubscribed $17 million "special purpose funding round" in order to expand its scalable mRNA manufacturing capability for its mRNA COVID-19 vaccine. The goal is to be able to produce billions of doses.
Rowan Walrath
May 12, 2020
AmericanInno
It's part of the company's larger pivot into life sciences.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.